Page 1005 - Read Online

Page 8 of 10 Kim et al. Hepatoma Res 2020;6:85 I http://dx.doi.org/10.20517/2394-5079.2020.96

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev
Gastroenterol Hepatol 2018;15:11.
2. Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016;10:394-406.
3. Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease.
Expert Rev Gastroenterol Hepatol 2011;5:253-63.
4. Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with
nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:1162-9.
5. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance,
familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61.
6. Chalasani N, Guo X, Loomba R, et al. Genome-wide association study identifies variants associated with histologic features of
nonalcoholic fatty liver disease. Gastroenterology 2010;139:1567-76.e6.
7. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet
2008;40:1461-5.
8. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty
liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
9. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of
common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
10. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 2018;68:268-79.
11. Kawaguchi T, Sumida Y, Umemura A, et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of
non-alcoholic fatty liver disease in Japanese. PLoS One 2012;7:e38322.
12. Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3)
polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep 2015;5:9284.
13. Dongiovanni P, Romeo S, Valenti L. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int
2015;2015:460190.
14. Dongiovanni P, Donati B, Fares R, et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol
2013;19:6969.
15. Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a
meta-analysis. Am J Gastroenterol 2014;109:325.
16. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-23.
17. Huang Y, He S, Li JZ, et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A 2010;107:7892-7.
18. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic
fatty liver disease. J Biol Chem 2011;286:37085-93.
19. BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid
droplets by evading ubiquitylation. Hepatology 2017;66:1111-24.
20. Luukkonen PK, Nick A, Hölttä-Vuori M, et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.
JCI Insight 2019;4:e127902.
21. Pingitore P, Dongiovanni P, Motta BM, et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol
Genet 2016;25:5212-22.
22. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, CRN N. The association of genetic variability in patatin‐like phospholipase
domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
23. Liu YL, Patman G, Leathart J, et al. Carriage of the PNPLA3 rs738409 C> G polymorphism confers an increased risk of non-alcoholic
fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
24. Carrion AF, Ghanta R, Carrasquillo O, Martin P. Chronic liver disease in the Hispanic population of the United States. Clin Gastroenterol
Hepatol 2011;9:834-41.
25. Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB
genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 2013;132:783-92.
26. Chung GE, Lee Y, Yim JY, et al. Genetic polymorphisms of PNPLA3 and SAMM50 are associated with nonalcoholic fatty liver disease
in a Korean population. Gut Liver 2018;12:316-23.
27. Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to
nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6.
28. Holmen OL, Zhang H, Fan Y, et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing